{"id":10160,"date":"2026-06-13T12:40:15","date_gmt":"2026-06-13T09:40:15","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=10160"},"modified":"2026-06-13T12:40:15","modified_gmt":"2026-06-13T09:40:15","slug":"1-month-dapt-after-current-generation-des-pci-may-be-best-for-high-bleeding-risk-patients","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/1-month-dapt-after-current-generation-des-pci-may-be-best-for-high-bleeding-risk-patients\/","title":{"rendered":"1-Month DAPT After Current-Generation DES PCI May Be Best for High-Bleeding-Risk Patients"},"content":{"rendered":"<p>1-Month DAPT After Current-Generation DES PCI May Be Best for High-Bleeding-Risk Patients<\/p>\n<p>Source : Published in Heart, the official journal of the British Cardiovascular Society (BCS).<br \/>\nMedscape June 11, 2026<\/p>\n<p>\u2022\u2060 \u2060A large network meta-analysis of 31 randomized trials involving 95,910 patients undergoing PCI evaluated the optimal duration of dual antiplatelet therapy (DAPT).<\/p>\n<p>\u2022\u2060 \u2060Five DAPT strategies were compared:<\/p>\n<p>\u2022\u2060 \u20601 month<br \/>\n\u2022\u2060 \u20603 months<br \/>\n\u2022\u2060 \u20606 months<br \/>\n\u2022\u2060 \u206012 months<br \/>\n\u2022\u2060 \u206012 months<\/p>\n<p>\u2022\u2060 \u2060Primary outcome: Net Adverse Clinical Events (NACE), including death, myocardial infarction (MI), stroke, bleeding, and stent thrombosis.<\/p>\n<p>Key Findings<\/p>\n<p>\u2022\u2060 \u20601-month DAPT showed the lowest overall risk of NACE, significantly outperforming:<\/p>\n<p>\u2022\u2060 \u20603-month DAPT (RR 0.74)<br \/>\n\u2022\u2060 \u20606-month DAPT (RR 0.63)<br \/>\n\u2022\u2060 \u206012-month DAPT (RR 0.67)<\/p>\n<p>\u2022\u2060 \u2060Rates of:<\/p>\n<p>\u2022\u2060 \u2060Death<br \/>\n\u2022\u2060 \u2060Stroke<br \/>\n\u2022\u2060 \u2060Stent thrombosis<\/p>\n<p>were similar across all treatment durations.<\/p>\n<p>\u2022\u2060 \u2060However, myocardial infarction risk was higher with 1-month DAPT compared with &gt;12-month therapy:<\/p>\n<p>\u2022\u2060 \u2060Bleeding risk was substantially lower with 1-month DAPT:<\/p>\n<p>\u2022\u2060 \u206043% lower vs 12-month DAPT<br \/>\n\u2022\u2060 \u206053% lower vs &gt;12-month DAPT<\/p>\n<p>Clinical Interpretation<\/p>\n<p>\u2022\u2060 \u2060The reduction in bleeding events with 1-month DAPT was greater in absolute terms than the increase in MI risk.<\/p>\n<p>\u2022\u2060 \u2060These findings suggest that for many contemporary PCI patients, particularly those at higher bleeding risk, ultra-short DAPT may provide the most favorable overall risk-benefit balance.<\/p>\n<p>\u2022\u2060 \u2060Longer DAPT durations continue to offer greater protection against MI, highlighting the importance of individualized treatment decisions based on ischemic versus bleeding risk.<\/p>\n<p>Source: Published in Heart, June 2026.<\/p>\n<p>Take-Home Message :<br \/>\nIn the era of contemporary DES, 1-month DAPT may provide the most favorable profile in high-bleeding-risk patients, while<br \/>\nlonger DAPT remains favored in high-risk ACS (e.g., STEMI, diabetes, multivessel disease, CKD, reduced LVEF, prior MI) and in complex PCI.<\/p>\n<p><a href=\"https:\/\/click.mail.medscape.com\/?qs=ABB7InYiOjEsImQiOjQ5MDV9AAYAAAAAAfeLqVOsRdj3wc7xDZj_T1Ndcx-ZivPezRzvZNxDmIHJWkbS3oteesao8fgjyYAsgXYVOC9fp7WA06-F80iCi1hmIN-v0Q7qqcABTIFfizM\">https:\/\/click.mail.medscape.com\/?qs=ABB7InYiOjEsImQiOjQ5MDV9AAYAAAAAAfeLqVOsRdj3wc7xDZj_T1Ndcx-ZivPezRzvZNxDmIHJWkbS3oteesao8fgjyYAsgXYVOC9fp7WA06-F80iCi1hmIN-v0Q7qqcABTIFfizM<\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>1-Month DAPT After Current-Generation DES PCI May Be Best for High-Bleeding-Risk Patients Source : Published in Heart, the official journal of the British Cardiovascular Society (BCS). Medscape June 11, 2026 \u2022\u2060 \u2060A large network meta-analysis of 31 randomized trials involving 95,910 patients undergoing PCI evaluated the optimal duration of dual antiplatelet therapy (DAPT). \u2022\u2060 \u2060Five [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-10160","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=10160"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10160\/revisions"}],"predecessor-version":[{"id":10161,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10160\/revisions\/10161"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=10160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=10160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=10160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}